ARS Pharmaceuticals, Inc. (SPRY)
ARS Pharmaceuticals, Inc. (SPRY)
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 24,321 | 41,317 | 59,557 | 51,540 |
| Short-term investments | 176,648 | 203,669 | 228,652 | 188,590 |
| Accounts receivable, net | 28,662 | 25,347 | 36,451 | 25,126 |
| Inventories | 8,817 | 8,369 | 7,782 | 8,738 |
| Prepaid expenses and other current assets | 6,788 | 6,194 | 6,421 | 7,442 |
| Right-of-use asset | NaN | NaN | 1,439 | 1,564 |
| Total current assets | 245,236 | 284,896 | 338,863 | 281,436 |
| Inventories, noncurrent | 23,221 | 23,053 | 13,645 | 13,374 |
| Property, plant and equipment, net | 2,285 | 2,465 | 1,209 | 1,075 |
| Intangible assets, net | 14,176 | 14,452 | 14,729 | 12,972 |
| Other assets | 2,653 | 2,786 | 2,918 | 3,051 |
| Total assets | 287,571 | 327,652 | 372,803 | 313,472 |
| Accounts payable | 4,705 | NaN | NaN | NaN |
| Accrued marketing related expenses | 20,411 | NaN | NaN | NaN |
| Accrued gross-to-net liabilities | 15,362 | NaN | NaN | NaN |
| Accrued cost of goods sold | 1,847 | NaN | NaN | NaN |
| Accrued inventory | 95 | NaN | NaN | NaN |
| Other | 5,843 | NaN | NaN | NaN |
| Lease liability, current | NaN | NaN | 583 | 589 |
| Accounts payable and accrued liabilities (including related party amounts of 1,431 and 1,624, respectively) | 48,263 | 37,948 | 49,768 | 44,264 |
| Contract liability, current | 757 | 609 | 526 | 746 |
| Other current liabilities | 592 | 588 | NaN | NaN |
| Total current liabilities | 49,612 | 39,145 | 50,877 | 45,599 |
| Term loans, net (including related party amounts of 4,826 and 4,819, respectively) | 96,522 | 96,374 | 96,229 | NaN |
| Lease liability, net of current portion | NaN | NaN | 949 | 1,072 |
| Financing liability | 74,673 | 72,140 | 72,044 | 71,959 |
| Contract liability, net of current portion | 978 | 1,130 | 1,268 | 1,103 |
| Other accrued liabilities | 4,478 | 4,605 | 3,781 | 1,418 |
| Total liabilities | 226,263 | 213,394 | 225,148 | 121,151 |
| Common stock, 0.0001 par value per share 200,000,000 shares authorized at march 31, 2026 and december 31, 2025 99,300,137 and 99,290,926 shares issued and outstanding at march 31, 2026 and december 31, 2025, respectively | 10 | 10 | 10 | 10 |
| Additionalpaid-incapital | 416,615 | 408,726 | 400,931 | 394,485 |
| Accumulated other comprehensive (loss) gain, net | -96 | 125 | -7 | -46 |
| Accumulated deficit | -355,221 | -294,603 | -253,279 | -202,128 |
| Total stockholders' equity | 61,308 | 114,258 | 147,655 | 192,321 |
| Total liabilities and stockholders' equity | 287,571 | 327,652 | 372,803 | 313,472 |